(Q54323537)

27 May 2018

title

Intravenous nitroglycerin-induced heparin resistance: a qualitative antithrombin III abnormality. (English)

1 reference

27 May 2018

1 reference

R C Becker

1

1 reference

27 May 2018

J M Corrao

2

1 reference

27 May 2018

E G Bovill

3

1 reference

27 May 2018

J M Gore

4

1 reference

27 May 2018

S P Baker

5

1 reference

27 May 2018

M L Miller

6

1 reference

27 May 2018

F V Lucas

7

1 reference

27 May 2018

J A Alpert

8

1 reference

27 May 2018

language of work or name

English

0 references

publication date

1 June 1990

1 reference

27 May 2018

published in

American Heart Journal

1 reference

27 May 2018

volume

119

1 reference

27 May 2018

issue

6

1 reference

27 May 2018

page(s)

1254-1261

1 reference

27 May 2018

Insights into the pathogenesis of acute ischemic syndromes

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2805%2980172-3

Role of platelets and thrombosis in coronary atherosclerotic disease and sudden death

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2805%2980172-3

Coronary angioscopy in patients with unstable angina pectoris

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2805%2980172-3

Unstable angina with fatal outcome: dynamic coronary thrombosis leading to infarction and/or sudden death. Autopsy evidence of recurrent mural thrombosis with peripheral embolization culminating in total vascular occlusion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2805%2980172-3

Anatomic-physiologic links between acute coronary syndromes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2805%2980172-3

Propylene glycol-induced heparin resistance during nitroglycerin infusion.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2805%2980172-3

Intravenous nitroglycerin and heparin resistance.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2805%2980172-3

Intravenous infusion of nitroglycerin in normal subjects.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2805%2980172-3

Intravenous nitroglycerin: clinical pharmacology and therapeutic considerations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2805%2980172-3

Nitroglycerin Pharmacokinetics After Intravenous Infusion in Normal Subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2805%2980172-3

Pharmacokinetic Studies of Standard Unfractionated Heparin, and Low Molecular Weight Heparins in the Rabbit

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2805%2980172-3

Structure-activity relationship in heparin: a synthetic pentasaccharide with high affinity for antithrombin III and eliciting high anti-factor Xa activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2805%2980172-3

Identification in vitro of an endothelial cell surface cofactor for antithrombin III. Parallel studies with isolated perfused rat hearts and microcarrier cultures of bovine endothelium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2805%2980172-3

Heparinlike molecules with anticoagulant activity are synthesized by cultured endothelial cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2805%2980172-3

Familial functional antithrombin III deficiency

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2805%2980172-3

Does nitroglycerin induce heparin resistance?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2805%2980172-3

Trial of heparin versus atenolol in prevention of myocardial infarction in intermediate coronary syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2805%2980172-3

Aspirin, heparin, or both to treat acute unstable angina

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2805%2980172-3

Enhancement of thrombolysis with tissue-type plasminogen activator by pretreatment with heparin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2805%2980172-3

Importance of continued activation of thrombin reflected by fibrinopeptide A to the efficacy of thrombolysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2805%2980172-3

Rethrombosis after reperfusion with streptokinase: importance of geometry of residual lesions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2805%2980172-3

Plaque rupture with severe pre-existing stenosis precipitating coronary thrombosis. Characteristics of coronary atherosclerotic plaques underlying fatal occlusive thrombi

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2805%2980172-3

Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2805%2980172-3

Importance of adequate heparin dosage in arterial angioplasty in a porcine model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2805%2980172-3

Evidence by Chemical Modification for the Involvement of One or More Tryptophanyl Residues of Bovine Antithrombin in the Binding of High-Affinity Heparin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2805%2980172-3

Tryptophan residue at the heparin binding site in antithrombin III

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2805%2980172-3

10.1016/S0002-8703(05)80172-3

7 January 2021

Identifiers

DOI

1 reference

27 May 2018

1 reference

27 May 2018